Advertisement
Table 3 Distribution of primary and secondary study endpoints as well as preservation solutions to the different eras, 580 patients from the Kiel liver transplant program
| Era | |||||
|---|---|---|---|---|---|
| I | II | III | IV | p-value | |
| n (%) | 9 (1.6%) | 96 (16.6%) | 152 (26.2%) | 323 (55.7%) | n.a. |
| HTK | 0 (0%) | 8 (8.3%) | 68 (44.7%) | 281 (87.0%) | <0.0011 |
| UW | 9 (100.0%) | 88 (91.7%) | 84 (55.3%) | 42 (13%) | <0.0011 |
| 3 months mortality | 3 (33.3%) | 22 (22.9%) | 35 (23.0%) | 32 (9.9%) | <0.0011 |
| graft loss | 8 (88.9%) | 59 (61.5%) | 75 (49.7%) | 85 (26.5%) | <0.0011 |
| 3 month graft survival | 6 (66.7%) | 68 (70.8%) | 106 (69.7%) | 262 (81.1%) | 0.0211 |
| Biliary complications | 1 (11.1%) | 33 (34.4%) | 47 (30.9%) | 18 (19.4%) | 0.0991 |
